Pulmocide Raises $92 Million in a Series C Financing to Fund Registration Program for PC945 May 27, 2021
J&J-Backed Pulmocide Fills its Lungs with $92M Series C to Fund Phase 3, Ahead of Possible IPO May 27, 2021
A UK Antifungal Player with a Big Pharma Pedigree Bags Fresh Round of Cash as it Races Toward Late-Stage Trial May 27, 2021
New JV from Upstart Biotechs Pyxis, Alloy Aims for Rapid Drug Development in Cancer, Autoimmune Diseases May 26, 2021
